Ionis Pharmaceuticals
IONS
375 hedge funds and large institutions have $7.09B invested in Ionis Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 123 increasing their positions, 131 reducing their positions, and 34 closing their positions.
47% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 34
27% more capital invested
Capital invested by funds: $5.6B → $7.09B (+$1.49B)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
4% more funds holding
Funds holding: 362 → 375 (+13)
1.3% more ownership
Funds ownership: 84.99% → 86.28% (+1.3%)
6% less repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 131
12% less call options, than puts
Call options by funds: $42.7M | Put options by funds: $48.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$270M |
| 2 |
BlackRock
New York
|
+$26.9M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$20.2M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$18.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$125M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$29.3M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$29M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$26.5M |
| 5 |
ClearBridge Investments
New York
|
-$20.7M |
IONS Hedge Fund Activity: Q2 2020 in Review
375 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2020, worth a combined $7.09B — up 27% from $5.6B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new IONS positions and 34 closed out — a net gain of 16 holders — while 123 added to existing stakes and 131 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $270M. The largest seller was Wellington Management Group, cutting an estimated $125M.
- 375 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2020, up from 362 in Q1 2020.
- Funds reported $7.09B of Ionis Pharmaceuticals stock for Q2 2020, up 27% quarter-over-quarter.
- 50 funds opened new Ionis Pharmaceuticals positions in Q2 2020 and 34 closed out, a net change of +16 holders.
- The largest Ionis Pharmaceuticals buyer in Q2 2020 was T. Rowe Price Associates, an estimated $270M added.
- The largest Ionis Pharmaceuticals seller in Q2 2020 was Wellington Management Group, an estimated $125M sold.
Based on aggregated 13F filings for Q2 2020.